Login to Your Account

In The Clinic NEWS

SHANGHAI – A transdermal pain patch being studied by Frontier Biotechnologies Inc., of Nanjing, China, has met its primary endpoints in a U.S. phase II trial of 146 patients with chronic lower back pain.

SHANGHAI – Hutchison China Meditech Ltd. is a biopharma unwilling to leave any stone unturned with its c-Met inhibitor, savolitinib. The Nasdaq-listed, China-based company has 11 clinical trials in 17 different indications for savolitinib.

LONDON – Circassia Pharmaceutical plc's lead immunotherapy program has flopped in a phase III 1,200 -subject trial in cat allergy, sending the shares of the UK's most valuable biotech crashing down by 66 percent.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: